Safety and Efficacy Study of a New Device for Tattoo Removal

The recruitment status of this study is unknown because the information has not been verified recently.
Verified December 2006 by Assaf-Harofeh Medical Center.
Recruitment status was  Not yet recruiting
Sponsor:
Collaborator:
Hawk Medical Ltd.
Information provided by:
Assaf-Harofeh Medical Center
ClinicalTrials.gov Identifier:
NCT00409162
First received: December 7, 2006
Last updated: NA
Last verified: December 2006
History: No changes posted

December 7, 2006
December 7, 2006
December 2006
Not Provided
  • Pigment clearance, as evaluated by image comparison on a 1-5 analog scale
  • Rate of systemic and dermatologic adverse events
  • Pharmacokinetic data for washing fluid (Cmax and AUC)
Same as current
No Changes Posted
Not Provided
Not Provided
Not Provided
Not Provided
 
Safety and Efficacy Study of a New Device for Tattoo Removal
A Prospective, Open Label, Non Randomized, First-In-Man (Feasibility) Study to Evaluate the Safety and Effectiveness of the Eraser Tattoo Removal Device

A new mechanical device is evaluated for tattoo removal, comparing two types of needle washing fluids. 30 healthy subjects with tattoos will be treated. The study hypothesis is that the device can be used to achieve satisfactory tattoo removal.

The new device (Eraser TM) uses multiple needles action with a washing fluid to remove tattoos. Healthy patients who wish to remove a tattoo will be enrolled. The study will test the removal of a small part of the tattoo (5cm2 area). Treatment lasts about 20 minutes (with local analgesia if needed), after which an absorptive bandage is put over the treated area for an hour and removed. Treatment may be performed using one of two washing fluids. For one of them, blood samples for material blood level will be taken before and several times after treatment. Pictures of the tattooed area being removed will be taken before and after treatment, and at each follow-up evaluation.

Follow up evaluations will be performed at 1 week, two weeks, one month and two months post treatment. Overall health and skin condition will be evaluated, and the tattoo area will be pictured. Efficacy of tattoo removal will be evaluated after two months, by visual estimation of the percent area that reacted to treatment, and the change in brightness (both evaluated on a 1-5 analog scale). Depending on the result of tattoo removal, and on skin condition, the study treatment will be stopped (if treatment is successful), or may be repeated (up to a limit of two additional times) if the tattoo was not completely removed.

The results of tattoo removal using both washing fluids will be analyzed and compared. A result of 3 or more on the brightness change scale will be considered as a successful treatment.

Pharmacokinetic data for washing fluid no. 2 will be collected and analyzed, to provide Cmax and AUC.

Interventional
Not Provided
Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
  • Tattoo
  • Healthy
Device: Eraser TM device, with washing fluid
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Not yet recruiting
30
October 2007
Not Provided

Inclusion Criteria:

  • Male or female subjects 18 years or older, of any race
  • Subject has a tattoo for removal on the back, shoulders or abdomen (areas that can usually be hidden)
  • Subjects willing to participate as evidenced by signing the written informed consent

Exclusion Criteria:

  • Subject has a dermatological disease, active or latent (e.g. psoriasis)
  • Subject has a known tendency for Keloid formation.
  • Subject has a known tendency for skin hyperpigmentation.
  • Subject is susceptible to Koebner reaction.
  • Subject has blood transmittable diseases (HIV, HBV, HCV, etc.)
  • Subject has known allergy to device components/ treatment fluids
  • Subject has medical conditions that may be worsened by concomitant use of washing fluid, or worsened by local anesthesia materials.
  • Subject is taking certain medications or topical preparations.
  • Female subject who is pregnant or lactating.
  • Subject participating in any other clinical study at the same time
Both
18 Years and older
Yes
Contact: Ori Nesher 00-1-972-54-6511141 ori@hawkmedical.com
Israel
 
NCT00409162
HTA 3722; 91/06, HM-AHR-1 Rev. 02
Not Provided
Not Provided
Assaf-Harofeh Medical Center
Hawk Medical Ltd.
Principal Investigator: Shay Efrati, MD Assaf Harofe Medical Center
Assaf-Harofeh Medical Center
December 2006

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP